GENEVA — Gene-editing technologies based on CRISPR and related molecular systems are advancing toward broader clinical use, with recent developments in base editing, prime editing and in vivo gene therapies expanding the scope of experimental treatments for genetic disease, according to peer-reviewed studies and regulatory updates published in 2026.
Researchers and biotechnology companies have reported progress in applying programmable genome-editing tools beyond laboratory and early-stage trials, including therapies targeting inherited blood disorders, cardiovascular disease and rare genetic conditions. A June 2026 review in Gene Therapy noted that genome editing has shifted from experimental use toward “clinically relevant” strategies capable of correcting or modulating disease-causing genes in human patients .
The field’s momentum has been reinforced by ongoing clinical trials using CRISPR–Cas9 systems and newer approaches such as base editing and prime editing, which enable more precise DNA modifications without introducing double-strand breaks. A March 2026 review of clinical trials identified dozens of studies involving gene-editing interventions across hematologic cancers, hemoglobin disorders and rare diseases, with CRISPR-Cas9 remaining the most widely used platform .
In parallel, industry-led programs have reported late-stage trial results for in vivo CRISPR therapies. In May, Intellia Therapeutics said its investigational treatment lonvoguran ziclumeran met primary and secondary endpoints in a Phase 3 trial for hereditary angioedema, and the company initiated a rolling submission to the U.S. Food and Drug Administration, according to a report in Nature Biotechnology .
Base editing and prime editing technologies are also moving into early human studies, primarily targeting monogenic diseases and liver-related conditions, according to peer-reviewed analyses published in 2026. These approaches aim to improve precision and reduce unintended DNA damage compared with earlier CRISPR methods .
Separately, scientists at the Broad Institute reported improvements to prime editing components and delivery systems, including lipid nanoparticle-based approaches designed to enhance in vivo efficiency, according to institutional updates published in June 2026 .
Clinical applications have already reached limited regulatory approval in specific cases. CRISPR-based therapy Casgevy has been authorized in multiple jurisdictions for sickle cell disease, and real-world use continues to expand following initial approvals in earlier years, according to regulatory and clinical reporting cited in 2026 literature .
Experts continue to emphasize that delivery efficiency, off-target effects and long-term safety monitoring remain key challenges before broader deployment of gene-editing therapies. A 2026 scoping review of clinical trials found that while early results are promising, most studies remain in Phase 1 or Phase 2 stages, with relatively few therapies reaching late-stage trials or approval .
As of June 28, 2026, gene-editing research programs and clinical trials continue to expand globally, with additional regulatory submissions and ongoing patient follow-up studies expected to shape the next phase of clinical evaluation.
